Immune checkpoint inhibitors (ICIs) that target either programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) have shown tremendous progress in the treatment of various types of cancer, including the ESCC [6]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.